Rotigotine patches (neupro) in early Parkinson's disease
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Parkinson's disease (PD) is a neurodegenerative disorder secondary to the progressive loss of dopaminergic neurons in the substantia nigra (a portion of the midbrain responsible for movement initiation and coordination) and appearance of bradykinesia, resting tremor, rigidity and postural reflex impairment. The most common symptomatic therapy is levodopa, a dopamine precursor; however, long-term treatment leads to involuntary movements and response fluctuations which add to the complexities of later disease-management. Monotherapy with dopamine agonists may represent an alternative approach with a reduced likelihood of motor complications; these drugs, initially introduced as adjunctive therapy to levodopa, are less effective in controlling motor disability and tend to cause more side effects than levodopa itself.
inDicatiOnS anD DOSinG
Rotigotine is a new chemical substance belonging to the group of non-ergolinic dopamine agonists. This drug is used for the treatment of early-stage Parkinson disease as monotherapy, or with levodopa at all stages of the disease. The drug is available in transdermal patches of several sizes, containing different doses of rotigotine (Table I) .
Recently, the Committee for Medicinal Products for Human Use (CHMP) of the EMEA issued a positive opinion on marketing authorization for rotigotine for idiopathic Restless Legs Syndrome (RLS) treatment. Rotigotine is currently included by AIFA (Agenzia Italiana del Farmaco) in a drug efficacy and safety monitoring program.
In early PD, the starting dose is 2mg/24h (4mg/24h for advanced PD), increased every week by 2mg/24h until an effective dose is reached, or up to a maximum dose of 8mg/24h (16mg/24h for advanced PD). 
PhaRmacOkineticS
The drug in the patch is constantly and dose-proportionately released over 24-h, resulting in constant plasmatic concentrations with daily application. The absorption of rotigotine is not influenced by gender, age, race, impaired renal or hepatic function. Rotigotine is widely distributed into tissues and extensively metabolized; the drug and its metabolites are mainly excreted in urine and less in bile and stool. 
FaRmacODynamicS
Rotigotine acts like a typical dopamine-agonist: this drug shows a close structural and functional analogy to dopamine, with a similar receptor binding and functional profile. Rotigotine is an agonist at all dopamine receptors, showing highest affinity and activity via the D3 receptor (the most widely cited receptor in the inhibition of locomotor activity).
eFFicacy anD SaFety
The clinical development program for the rotigotine patch comprised four main studies (Phase III trials ): SP512 and SP513 to evaluate rotigotine efficacy in monotherapy in early-stage idiopathic PD; SP650 and SP515 to evaluate rotigotine efficacy in combination with levodopa in advanced idiopathic PD. SP512 and SP650 trials were placebo-controlled, whereas SP513 and SP515 were controlled against another dopamine agonist (ropinirole and pramipexole, respectively).
The primary efficacy end-point for monotherapy trials was based upon the UPDRS II/III score (Unified Parkinson's disease rating scale, a compilation of various PD assessment scales, the most frequently used for evaluating treatment responses), whereas for the evaluation of rotigotine in combination with levodopa the primary variable was the change in absolute time spent "off" (time during which PD symptoms are most prominent).
The safety profile of rotigotine can be considered typical of a dopamine-agonistic agent, with adverse reactions (AEs) like nausea, somnolence, vomiting, fatigue and constipation; the only exception is the high frequency of skin reactions in the application site. An increased frequency of AEs was observed in adjuvant therapy with levodopa, as compared to monotherapy. * UPDRS score (Unified Parkinson's disease rating scale) in part II (daily activities) and III (motor evaluations) of questionnaire is the primary efficacy end-point for monotherapy trials; maximum score is 160 (52 + 108) points (worst scenario) and the absence of disease signs is associated with a 0 score AEs = adverse events ; P = placebo; Pr = pramipexole; Rp = ropinirole; Rt = rotigotine ecOnOmic evaLUatiOnS We were not able to retrieve any published economic evaluation on the use of rotigotine in Parkinson disease.
In table IV we calculated monthly pharmaceutical costs for available therapies for PD treatment. For each formulation we valorized minimum and maximum dosing (from the Summary Product Characteristics -SPCs) and DDD (Defined Daily Dose) for one month of therapy, using retail price. For packages with identical price we considered the less costly one. This is not to be intended as a cost-minimization analysis, but as a simple overlook of currently available treatments. 
